1. Turn sample approval into a production specification
Agree which sample version represents the product being ordered. Record the formula reference, fragrance or shade, fill size and approved packaging configuration. A physical sample and a written specification serve different purposes: one provides a comparison reference, while the other defines what will be assessed.
For example, a buyer may describe a cream as light and fast-absorbing. Before production, ask how that expectation will be compared with the reference and which measurable specifications are relevant. Have the technical team set appropriate methods and limits. Keep any unresolved product redesign separate from the scale-up decision.
2. Review the process transfer with the manufacturing team
Ask the technical team to explain the proposed route from laboratory preparation to production equipment. The useful question is what needs to be confirmed, rather than whether the ingredient quantities can simply be multiplied. Discuss ingredient addition, mixing, temperature control, holding, transfer and filling where relevant to the formula.
FDA's cosmetic GMP inspection checklist identifies written manufacturing instructions and production records as important controls. For the buyer, a practical next step is to request a summary of open transfer questions and who will resolve them. Agree the confidentiality arrangements for any customer-owned formula before sharing technical files.
Sources for this section: [2]
3. Define what a pilot batch needs to demonstrate
A pilot batch should answer specified production questions. Ask why the proposed trial is representative and what observations will determine the next decision. Its scope should reflect the formula and manufacturing route; there is no universal pilot quantity suitable for every project.
Cosmetics Europe/CTFA's 2004 guidance discusses equipment representative of commercial manufacture when assessing scale-up stability, considering process, batch size and product type. Discuss missing evidence and when it will be reviewed. Put the trial objective and review point in writing before scheduling it.
Sources for this section: [1]
4. Include the final pack and filling configuration
Discuss the intended container, closure, dispensing system and filling route together. The Cosmetics Europe/CTFA guidance also addresses formula–container compatibility and testing in representative packaging.
For purchasing, identify exactly which components will be used in the trial and which are still provisional. Ask the team to review filling and dispensing performance. Record any remaining component decision so a later bottle, pump or liner substitution triggers a review before use. Agree who will notify the buyer of a proposed substitution and how that decision will be documented.
Sources for this section: [1]
5. Use a shared pilot-to-bulk confirmation checklist
Use this table as a discussion sheet. Assign a named owner and a written status to each item. The manufacturer should adapt the technical details to the product; the buyer should confirm commercial decisions and approval responsibilities.
| Decision | Confirm before the trial | Confirm before bulk production |
|---|---|---|
| Product reference | Agreed formula and sample version | Any changes reviewed and approved |
| Process transfer | Trial objective and proposed equipment | Outstanding transfer questions resolved |
| Packaging | Trial components and provisional items | Final components and artwork confirmed |
| Technical evidence | Checks, methods and review responsibilities | Required evidence assessed against the project plan |
| Exceptions | How unexpected results will be reported | Open issues resolved or given a documented disposition |
| Order readiness | Quantity, destination and timing assumptions | Current quotation and production conditions accepted |
6. Separate buyer approval from quality release
Define who can approve appearance and sensory references, who assesses technical results, and who authorizes release of the finished batch. A buyer's approval email should state its scope.
FDA's cosmetic GMP checklist covers checks on raw materials, in-process samples and finished products, together with batch and test records. Ask which results or summaries will accompany your order and how batch identification will appear on the goods. Documentation availability should be agreed in advance. This checklist is a planning reference, not evidence that a particular supplier or batch meets every applicable requirement.
Sources for this section: [2]
7. Build the order schedule around unresolved decisions
Ask for a schedule that identifies dependencies: technical review, trial work where needed, packaging availability, artwork confirmation and required evidence. Discuss which activities can proceed together and which require a prior decision.
Confirm how an unsuccessful trial or a requested change would affect costs and timing before committing to launch materials. MOQ, price and lead time depend on the agreed formula, packaging and order plan. A useful bulk-production decision closes the remaining questions and records the conditions under which the order can proceed.